copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
DNA Damage Response | DDR Company | Artios Pharma Artios is a leading independent DDR Company with a strong pipeline of novel cancer therapies in development with first-in-class best-in-class potential
About Artios | Leadership | Scientific Advisors | Board Artios is leading the DNA Damage Response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of pioneering DDR drug developers
Pipeline - Artios Pharma Artios plans to initiate a Phase 2 trial with ART6043 in combination with olaparib Artios is also exploring the potential of Polθ with DNA damaging agents such as chemotherapies, ionizing radiation and radioligand therapy as well as with immuno-oncology medicines
News Events - Artios Pharma Artios Pharma to Present at the 43rd Annual J P Morgan Healthcare Conference 19 December 2024 | Press release
Artios Pharma Announces Details of Presentations at the American . . . CAMBRIDGE, United Kingdom and NEW YORK, April 15, 2025 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today announced that the company’s abstract featuring clinical trial results from its ongoing Phase 1 2a study of ART0380 in combination with low
DNA Damage Response | Clinical Trials - Artios Pharma Targeting DNA Damage Response (DDR) pathways Artios leverages its unparalleled insights into the ensemble of DDR pathways within cells to go beyond synthetic lethality, unlocking new opportunities for patients with hard-to-treat cancers
First results from the phase I trial of the ATR inhibitor . . . - Artios Ataxia-telangiectasia-mutated (ATM) deficiency identified by Artios’ ATR-ID algorithm (bespoke algorithm to predict ATM protein deficiency using mutational impact) or IHC H-score ≤10, or percentage staining at 0 in ≥90% of tumor cells
ART6043 Pol Theta Inhibitor - Artios Pharma Our Polθ inhibitor offers the potential to harness the power of the DDR inhibition to specifically target tumor cells while sparing normal tissue from toxicity It may allow for effective and widespread use across multiple tumor types including PARP inhibitor resistant cancers, as a combination treatment with other DDR inhibitors, or in combination with ionizing radiation ART6043 is an